amorcyte amorcyte amorcyte amorcyte amorcyte
amorcyte amorcyte amorcyte amorcyte amorcyte
amorcyte amorcyte
Amorcyte Logo
Cell Therapy Solutions for Cardiovascular Disease amorcyte home amorcyte contact us amorcyte
amorcyte
amorcyte
amorcyte
amorcyte



amorcyte
amorcyte
Amorcyte, a NeoStem company, develops cell therapy products to treat cardiovascular disease.

Its lead product candidate, AMR-001, for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed Phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. This is the first prospective stem cell trial in AMI ever conducted that has established a statistically significant relationship between dose and effect. Amorcyte is now open for enrollment of patients for the PreSERVE AMI Phase II trial. The trial has been designed to evaluate the potential of AMR-001 to improve perfusion, preserve cardiac function and improve clinical outcomes.

Amorcyte will be provided with a pharmaceutical grade cGMP manufactured product that can be distributed commercially by Progenitor Cell Therapy, another NeoStem company and a leading provider of clinical, manufacturing and other services for the cell therapy industry.

Click here, to download a fact sheet on Amorcyte and AMR-001.
amorcyte
amorcyte
amorcyte amorcyte amorcyte amorcyte
amorcyte
amorcyte
amorcyte

amorcyte
amorcyte
AMORCYTE, A NEOSTEM COMPANY, ENROLLS FIRST PATIENT IN PRESERVE PHASE 2 TRIAL FOR ACUTE MYOCARDIAL INFARCTION
amorcyte
amorcyte
New York, NY (January 25, 2012)
amorcyte
amorcytemore
amorcyte

SENIOR MANAGEMENT OF NEOSTEM AND ITS SUBSIDIARIES INVITED TO SPEAK AT SEVENTH INTERNATIONAL CONFERENCE ON CELL THERAPY FOR CARDIOVASCULAR DISEASE

amorcyte
amorcyte
New York, NY January 23, 2012)
amorcyte
amorcytemore
amorcyte

AMORCYTE, A NEOSTEM COMPANY, ANNOUNCES EXPANSION OF INTELLECTUAL PROPERTY

amorcyte
amorcyte
New York, NY (January 10, 2012)
amorcyte
amorcytemore
amorcyte

NEOSTEM ACQUIRES AMORCYTE, A CLINICAL STAGE CARDIOVASCULAR DISEASE CELL THERAPY COMPANY

amorcyte
amorcyte
New York, NY, October 17, 2011)
amorcyte
amorcytemore
amorcyte
amorcyteamorcyte
NEOSTEM PROVIDES UPDATE ON AMORCYTE CLINICAL PROGRESS AND REPORTS RESULTS FOR SECOND QUARTER
amorcyte
amorcyte
New York, NY, August 15, 2011
amorcyte
amorcytemore
amorcyte
amorcyteamorcyte
NEOSTEM SIGNS DEFINITIVE MERGER AGREEMENT TO ACQUIRE AMORCYTE IN EQUITY TRANSACTION
amorcyte
amorcyte
New York, NY, July 14, 2011
amorcyte
amorcytemore
amorcyte
amorcyte
amorcyte
AMORCYTE STEM CELL THERAPY DEMONSTRATES CLINICALLY SIGNIFICANT REPERFUSION IN SEVERE HEART ATTACK PATIENTS
amorcyte
American Heart Journal Publication Establishes Achievement of Threshold Dose
amorcyte
Allendale, NJ, December 21, 2010
amorcyte
amorcytemore
amorcyte
amorcyte
amorcyte

amorcyte amorcyte
amorcyte amorcyte
amorcyte amorcyte amorcyte
Back to Top
amorcyte amorcyte
amorcyte amorcyte amorcyte amorcyte amorcyte